Overview

A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology

Status:
Completed
Trial end date:
2017-02-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and pharmacokinetics and assess the immunogenicity and effectiveness of AGS-16C3F in subjects with renal cell cancer (RCC).
Phase:
Phase 1
Details
Lead Sponsor:
Agensys, Inc.